2026-04-28 11:49
期望讓投資人更有效率找到各種投資標的的投資事實。核心價值在於脂肪細胞標靶新藥CBL-514於區域性減脂及體重管理市場的長期授權與商轉潛力。減脂新藥題材帶動資金迴流+短線跌深反彈主力回補點火" height="405" src="https://image.cmoney.tw/official/assets/1751472000/c558bc5d-7e19-400f-826a-0e59ad7b3517.png" width="720">
????下載【籌碼K線】,留意壓力區與主力動向
技術面來看,屬於跌深後的短線反彈格局。股價近期自140元以上一路壓回,減脂及非侵入式醫美市場成長性佳,
Disclaimer: All text and images published on this site are adapted or collected from the Internet. We do not use them for any commercial purpose, and the copyright belongs to the original author. Since we cannot contact the copyright holders for some content, please contact us to delete it if it infringes or involves illegality. Please keep the original address for reprinting: http://www.jtlzs.com/news/26b2199952.html
Featured Reads
歐易交易所官網
歐易交易所平臺